Palbocent

Instructions for palbociclib

Common name: palbociclib

Trade name: palbociclib

All names: palbociclib, palbociclib, palbociclib, aibexin, palbocicli b, Ibrance, Palbonix

Introduction to palbociclib:

Palbociclib (palbociclib, also translated as: palbociclib) is the world's first cyclin-dependent kinase (CDK) 4/6 inhibitor. Due to its excellent efficacy and safety, palbociclib has been approved for marketing in more than 80 countries and regions around the world, and China is the 87th country to be approved for marketing. It is produced by Beacon Pharmaceuticals, a listed pharmaceutical company in Bangladesh, with the trade name: Palbonix.

Indications of palbociclib:

(1) In combination with letrozole, it is used to treat postmenopausal patients with ER-positive, HER2-negative advanced metastatic breast cancer.

(2) Combined with fulvestrant, it can be used in patients with ER-positive and HER2-negative breast cancer that have progressed after endocrine therapy.

Usage and dosage of palbocicillin:

The recommended starting dose is 125 mg once a day, in combination with letrozole, with meals, for a total of 21 days, and then stop taking the drug for 7 days.

Usage of palbocicillin in special groups:

Breastfeeding women should stop taking the drug or stop breastfeeding.

The therapeutic advantages of palbociclib:

(1) Good therapeutic effect: Compared with letrozole monotherapy, the combination of palbociclib and letrozole can more than double the progression-free survival of breast cancer. It is a new hope for breast cancer patients and has achieved a breakthrough in efficacy.

(2) Low incidence of adverse reactions: Palbociclib is a capsule that can be taken orally. Compared with injections, it is safer, easier for patients to take, and improves patient compliance. In addition, this drug does not have the side effects of traditional chemotherapy, such as intestinal reactions, which are mild.

(3) Strong targeting: Due to the increased level of Cyclin D in tumor cells, it can increase the sensitivity of cells to drugs and increase the targeting of drugs.

(4) Convenient to take: Palbociclib is an oral drug that only needs to be taken once a day, 125mg, for 3 consecutive weeks, with 1 week of rest, and is not restricted by location